<DOC>
	<DOCNO>NCT01418222</DOCNO>
	<brief_summary>This randomize , double-blind , placebo-controlled study evaluate efficacy safety FOLFOX/bevacizumab onartuzumab ( MetMAb ) versus placebo first-line treatment patient metastatic colorectal cancer .</brief_summary>
	<brief_title>FOLFOX/Bevacizumab With Onartuzumab ( MetMAb ) Versus Placebo First-Line Treatment Patients With Metastatic Colorectal Cancer</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Adult patient , &gt; /= 18 year age Histologically cytologically confirm adenocarcinoma colon rectum patient metastatic ( Stage IV ) disease Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 Measurable disease RECIST criterion Adequate organ system function , define protocol Prior systemic radiation therapy metastatic colorectal cancer Adjuvant chemotherapy ( and/or chemoradiation ) colorectal cancer within 12 month prior date diagnosis metastatic disease Previously untreated brain metastasis History hypersensitivity active inactive excipients component treatment , know dipyrimidine dehydrogenase deficiency Evidence bleed diathesis significant coagulopathy ( absence therapeutic anticoagulation ) History hematemesis hemoptysis &lt; /= 1 month prior study enrollment Significant cardiovascular disease disorder History abdominal fistula gastrointestinal perforation &lt; /= 6 month prior Day 1 Positive hepatitis B , hepatitis C HIV infection Other active cancer history treatment invasive cancer within last 5 year , except nonmelanoma skin cancer</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>